Clinical Trial Update: A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of intravitreal ANX007 in geographic atrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• ANX007

Snippet

Sponsor: Annexon, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED